Oman Pharmaceuticals & Healthcare Report

Published 10 December 2015

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position

Register for a FREE Executive Summary

Oman Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Oman's pharmaceuticals and healthcare market will remain an attractive investment proposition for international players. Despite the public sector holding the greatest market share, the private sector will play a pivotal role in healthcare expansion over the long term. The rising cost of medical services will be kept in check to an extent by the downward pressure on drug prices - mainly driven by the Gulf Cooperation Council's medicine price unification process. Over the long term, Oman's population will benefit from more affordable healthcare services as price unification becomes more standardised across the Gulf States.

Headline Expenditure Projections

  • Pharmaceuticals: OMR205mn (USD532mn) in 2014 to OMR219mn (USD568mn) in 2015; 6.8% in local currency and US dollar terms. Forecast in line with Q 4 15.

  • Healthcare: OMR885mn (USD2.30bn) in 2014 to OMR961mn (USD2.50bn) in 2015; +8.5% in local currency and US dollar terms. Forecast revised upwards from Q 4 15.

Headline Pharmaceuticals & Healthcare Forecasts (Oman 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.487 0.532 0.568 0.607 0.650 0.698 0.750
Pharmaceutical sales, % of GDP 0.62 0.65 0.82 0.85 0.87 0.89 0.90
Pharmaceutical sales, % of health expenditure 24.3 23.1 22.7 22.8 23.1 23.5 24.1
Health spending, USDbn 2.002 2.299 2.495 2.661 2.820 2.965 3.113

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population, low per capita spending on pharmaceuticals and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q116, Oman scores 49.0 out of 100 in BMI's Pharmaceutical Risk/Reward Index, moving up one position to eighth place out of 31 countries...

Register for a FREE Executive Summary

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2011-2019)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Oman 2013-2019)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2013-2019)
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Economic Analysis
34
Table: GCC - REAL GDP GROWTH, % CHG Y-O-Y
39
Table: Oman - Selected Infrastructure And Industrial Projects
41
Industry Risk Reward Indicies
43
Middle East and Africa Risk/Reward Index
43
Oman Risk/Reward Index
50
Rewards
50
Risks
51
Market Overview
52
Industry Trends And Developments
54
Industry Trends And Developments
54
Epidemiology
54
Communicable Diseases
55
Non-Communicable Diseases
56
Healthcare Sector
58
Table: Healthcare Resources (Oman 2009-2014)
58
Table: Healthcare Personnel (Oman 2009-2014)
58
Table: Healthcare Activity (Oman 2009-2014)
59
Public Healthcare Sector Developments
62
Private Healthcare Sector Developments
63
Table: Number Of Health Centres In Oman By Region In 2013
66
Table: Number And Type Of Health Institutions In Oman In 2014
66
Healthcare Insurance
67
Telemedicine
67
Medical Tourism
68
Research And Development
70
Clinical Trials
71
Regulatory Development
73
Regulatory Developments
74
Intellectual Property Regime
74
Regional Harmonisation
75
Pricing And Reimbursement Regime
76
Competitive Landscape
81
Domestic Pharmaceutical Industry
81
Foreign Pharmaceutical Industry
82
Pharmaceutical Distribution
83
Company Profile
84
GlaxoSmithKline
84
Johnson & Johnson
86
National Pharmaceutical Industries
88
Novartis
91
Sanofi
94
Zynova/Oman Pharmaceutical Products Company
96
Demographic Forecast
99
Table: Population Headline Indicators (Oman 1990-2025)
100
Table: Key Population Ratios (Oman 1990-2025)
100
Table: Urban/Rural Population & Life Expectancy (Oman 1990-2025)
101
Table: Population By Age Group (Oman 1990-2025)
101
Table: Population By Age Group % (Oman 1990-2025)
102
Glossary
104
Methodology
106
Pharmaceutical Expenditure Forecast Model
106
Healthcare Expenditure Forecast Model
106
Notes On Methodology
107
Risk/Reward Index Methodology
108
Index Overview
109
Table: Pharmaceutical Risk/Reward Index Indicators
109
Indicator Weightings
110

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.